Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Yusuke Daido; Hiroyuki Sugiura; Tatsunori Ishikawa; Taiga Kuroi; Sachiyo Okamoto; Naho Nomura; Taro Masunari; Nobuo Sezaki; Yasuhito Nannya; Seishi Ogawa; Mitsune Tanimoto

doi:10.1159/000533749

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Case Rep Oncol. 2023 Sep 22;16(1):999-1006. doi: 10.1159/000533749. eCollection 2023 Jan-Dec.

Authors

Affiliations

¹ Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Hiroshima, Japan.
² Division of Hematopoietic Disease Control, Advanced Clinical Research Center, Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
³ Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Abstract

Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haplo-PBSCT) from related donors appears to be a suitable option. Here, we report two elderly patients with refractory AML harboring an IDH2 mutation, who were successfully treated with VEN+AZA bridged to PTCy-haplo-PBSCT. This report suggests the efficacy and safety of VEN+AZA as a bridging treatment for PTCy-haplo-PBSCT in refractory AML.

Keywords: Acute myeloid leukemia; IDH2 mutation; PTCy-haplo-PBSCT; Venetoclax-azacitidine.

Publication types

Case Reports

Grants and funding

No funding was received for this study.